ReviewRecent advances in the neuropsychopharmacology of serotonergic hallucinogens
Introduction
Hallucinogenic drugs have been used by humans for thousands of years, but western scientists only became interested in these substances beginning in the late 1800s. These agents produce profound changes in consciousness. Because other drug classes can sometimes produce effects that overlap with those of the hallucinogens, it has been important to develop a formal definition for these compounds. This has turned out to be a difficult and contentious task. Hallucinogens have been defined as agents that alter thought, perception, and mood without producing memory impairment, delirium, or addiction [1], [2]. However, this definition is overly broad because it fails to exclude a wide-range of agents that are generally not classified as hallucinogens, such as cannabinoids and NMDA antagonists. It is now recognized that hallucinogens produce similar discriminative stimulus effects [3] and act as agonists of the serotonin-2A (5-HT2A) receptor [4]. Therefore, it has been proposed [5] that in addition to having the characteristics listed above, hallucinogens should also bind to the 5-HT2A receptor and produce full substitution in animals trained to discriminate the prototypical hallucinogen 2,5-dimethoxy-4-methylamphetamine (DOM). For this reason, hallucinogens are often categorized as classical hallucinogens or serotonergic hallucinogens. This article will review the pharmacology of hallucinogens, including their mechanism-of-action, their effects in animals and humans, and recent findings regarding how they interact with specific brain regions.
Section snippets
Receptor interactions
Classical hallucinogens can be divided into two main structural classes: indoleamines and phenylalkylamines [6]. Indoleamines include the tetracyclic ergoline (+)-lysergic acid diethylamide (LSD) and the chemically simpler indolealkylamines, which includes N,N-dimethyltryptamine (DMT), N,N-dipropyltryptamine (DPT), 5-methoxy-DMT (5-MeO-DMT), and psilocybin (4-phosphoryloxy-DMT) and its active O-dephosphorylated metabolite psilocin (4-hydroxy-DMT). DMT is found in several hallucinogenic snuffs
Subjective effects
Despite having different chemical structures, phenylalkylamine, tryptamine, and ergoline hallucinogens produce remarkably similar subjective effects [35], [36], [37], [38], [39], [40], [41], [42]. It is very difficult for hallucinogen-experienced subjects to distinguish between psilocybin and LSD if those substances are administered in a blinded fashion, with the only apparent difference being the duration of action [41]. Similar findings have been reported when mescaline, LSD, and psilocybin
Evidence from human studies
Multiple, converging lines of evidence point to 5-HT2A receptor activation as the unitary mechanism responsible for mediating hallucinogenesis. Indoleamine and phenylalkylamine hallucinogens bind to 5-HT2 sites with moderate to high affinity [80], [81], [82], [83]. Although indoleamine hallucinogens show relatively promiscuous binding profiles, phenylisopropylamine hallucinogens such as DOM and DOB are highly selective for 5-HT2 receptors [13], [15] and therefore it is likely that their effects
Locus coeruleus
The locus coeruleus (LC), located in the dorsal pons, is the source of almost all noradrenergic projections in the CNS. LC neurons are responsive to sensory stimuli, especially of a novel or arousing nature, and the firing of LC neurons is markedly increased by noxious stimulation (reviewed by: [230]). Intravenous administration of mescaline (2 mg/kg), LSD (5–10 μg/kg), DOM (20–80 μg/kg), DOB (50–100 μg/kg), or DOI (16–50 μg/kg) profoundly enhances the responses of LC neurons to sensory stimuli
Summary
Despite the complexity of hallucinogen effects, we are beginning to understand how these substances work in the brain. The 5-HT2A receptor was first identified about thirty years ago as a possible site of action of hallucinogens. It is now clear that most of the effects of hallucinogens are mediated by 5-HT2A activation. Although the vast majority of this evidence was derived from studies in animals, the resumption of human studies with hallucinogens has provided additional support.
Recent
Acknowledgements
This work was supported by grants from NIMH (K01 MH100644), NIDA (R01 DA002925), and the Brain and Behavior Research Foundation.
References (450)
- et al.
Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists
Eur J Pharmacol
(1983) Arylalkylamine drugs of abuse: an overview of drug discrimination studies
Pharmacol Biochem Behav
(1999)- et al.
Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of ayahuasca
J Ethnopharmacol
(1984) - et al.
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
Eur J Pharmacol
(2007) - et al.
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Neuropharmacology
(2011) - et al.
Stereospecific binding of d-lysergic acid diethylamide (LSD) to brain membranes: relationship to serotonin receptors
Brain Res
(1975) - et al.
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine
Neuropharmacology
(1986) - et al.
Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior
Neuron
(2007) - et al.
5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens
Pharmacol Biochem Behav
(2002) - et al.
Role of Gq protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
Neuropharmacology
(2007)
Mescaline, lysergic acid diethylamide and psilocyb comparison of clinical syndromes effects on color perception biochemical F measures
Comprehens Psychiatry
Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research
Biol Psychiatry
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis
Neuropsychopharmacology
Cross tolerance or tachyphylaxis among various psychotomimetic agents on cats
Eur J Pharmacol
5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA)
Eur J Pharmacol
Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens
Eur J Pharmacol
Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
Neuropharmacology
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Life Sci
Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors
Biol Psychiatry
Serotonin and schizophrenia
Hallucinogens as a discriminative stimuli: generalization of DOM to a 5-methoxy-N,N-dimethyltryptamine stimulus
Life Sci
Discriminative stimulus properties of the serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)
Life Sci
Psilocybin-induced stimulus control in the rat
Pharmacol Biochem Behav
Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents
Pharmacol Biochem Behav
Chemical psychoses: LAD and related drugs
Psychedelic drugs reconsidered
The use of the drug discrimination paradigm for studying hallucinogenic agents. A review
Structure-activity relationships of serotonin 5-HT2A agonists
WIREs Membr Transp Signal
Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists
Mol Pharmacol
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor
J Med Chem
1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists
J Med Chem
Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands
ACS Chem Neurosci
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)
J Med Chem
Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropyl amine hallucinogens
Psychopharmacology (Berl)
Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites
Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex
Psychopharmacology (Berl)
The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator
Science
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor
Mol Pharmacol
Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter
J Neural Transm
Two kinds of tryptamine receptor
Br J Pharmacol
Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors
Mol Pharmacol
Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine [3H]lysergic acid diethylamide and [3H]spiroperidol
Mol Pharmacol
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
Pharmacol Rev
A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases
J Neurochem
Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo
J Neurosci
5-HT2A receptor signalling through phospholipase D1 associated with its C-terminal tail
Biochem J
Serotonin 5-hydroxytryptamine2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves
J Pharmacol Exp Ther
Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo
Proc Natl Acad Sci U S A
Comparison of the reactions induced by psilocybin and LSD-25 in man
Psychopharmacologia
Clinical, biochemical and psychologic effects of psilocybin
Arch Int Pharmacodyn
Cited by (208)
Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights
2024, International ImmunopharmacologySynthetic surprise as the foundation of the psychedelic experience
2024, Neuroscience and Biobehavioral ReviewsEstablished sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT<inf>2A</inf> receptor agonist TCB-2 in male DBA/2J mice
2024, Pharmacology Biochemistry and BehaviorPresent and future of metabolic and metabolomics studies focused on classical psychedelics in humans
2023, Biomedicine and Pharmacotherapy